Funding Daily Summary
Funding Daily Summary: What Happened on October 3, 2026
Circle Pharma raises $92.5 million and prioritizes preclinical cyclin D1 drug
The day also brought venture rounds, an IPO filing, a new fund target and public funding for research.
-
M
P
B
Covers October 2 and October 3. There was no summary on October 2.
Today in brief
Circle Pharma's $92.5 million Series E will support its decision to put preclinical candidate CID-165 ahead of its Phase I lead program.1 Other funding news ranged from venture rounds and a new fund target to a UK commitment for dementia diagnosis.234
Circle puts preclinical CID-165 ahead of its clinical lead
Circle Pharma announced a $92.5 million Series E on September 16 and is making CID-165 its top development priority.1 The candidate inhibits cyclin D1, while CID-078, Circle’s cyclin A/B inhibitor, remains in Phase I.1
CEO David Earp said preclinical combination data drove the decision to prioritize CID-165.1 Circle plans to begin clinical development of CID-165 in early 2027, pursuing deeper responses in estrogen receptor-positive breast cancer by targeting another part of the pathway addressed by CDK4/6 drugs.1
Also worth knowing
-
M
On October 2, Enveda closed a $311 million Series E, Basecamp Research raised $140 million in a Series C, and BigHat Biosciences completed a $75 million Series C.2
-
M
On October 2, Iambic Therapeutics filed for a US IPO and announced a multiyear research collaboration with AbbVie.2
-
On October 2, Hatteras Venture Partners set a $100 million target for a second fund focused on follow-on investments in selected portfolio companies, nearly four times the predecessor fund’s size.3
-
P
On October 2, the UK committed £80 million to an effort to improve dementia diagnosis.4
-
B
On October 2, CaseBioscience joined a Likarda-led team selected for up to $7.3 million in ARPA-H support for cell-preservation research.5